Health and Human Services Secretary Robert F. Kennedy Jr. announced that the FDA will conduct a new review of the abortion pill mifepristone, used in nearly two-thirds of U.S. abortions.
The review follows a study citing higher complication rates than FDA label data and comes as abortion access remains restricted in many states post-Roe.
Kennedy and FDA Commissioner Marty Makary said the review will examine real-world outcomes and the drug’s safety, while abortion providers warn the move could further limit access to medication abortion nationwide.
Read more here.